While the exact pathogenesis of uterine fibroids remains unknown, the estrogen threshold hypothesis is an accepted theory that has led to the development of novel treatments for this condition, including gonadotropin-releasing hormone (GnRH) antagonists such as relugolix and elagolix. GnRH antagonists have been shown to be safe and effective treatments for patients with uterine fibroids, and their use can help to improve bleeding, discomfort, uterine fibroid size, and quality of life in premenopausal patients who are symptomatic. It is imperative that clinicians understand the estrogen threshold hypothesis and recognize the role of these novel treatments in the management of this condition.
In the second activity of this CME Outfitters Snack series, expert faculty will help learners to assess the role of GnRH antagonists in long-term treatment of uterine fibroids based on the latest data in alignment with the estrogen threshold hypothesis.
Assess the role of GnRH antagonists in long-term treatment based on the latest data and aligned to the estrogen threshold hypothesis.
Supported by an educational grant from Pfizer Inc. and Sumitomo Pharma America.
Obstetrician-gynecologists, primary care physicians, nurse practitioners (NPs), physician associates (PAs), and nurses.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Al-Hendy reports the following financial relationships:
Consultant: AbbVie Inc.; Bayer; Myovant Sciences; Norvartis Pharmaceuticals Corporation; ObsEva; and Pfizer Inc.
Research Support: CrilaHealth.
Dr. Marsh reports the following financial relationships:
Consultant: Alnylam; Myovant Sciences; and Pfizer Inc.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).